A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 750 participants.
Also called NCT07214376
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 750 participants
- Sponsor
- Pulnovo Medical, Inc.
- Registry
-
NCT07214376
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, China
- Registry status
- Recruiting
Technical summary
Registry record NCT07214376. Randomized; double masking; primary purpose treatment. Start 2026-08-21 (actual); primary completion 2029-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
- Acronym
- The PULSE-LHD
- Condition
- Pulmonary Hypertension
- Condition
- Hypertension
- Condition
- Vascular Diseases
- Condition
- Cardiovascular Diseases
- Condition
- Heart Failure
- Condition
- Heart Failure With Mid Range Ejection Fraction
- Intervention (Device)
- Pulmonary Artery Denervation (PADN)
- Intervention (Device)
- Sham procedure control
- Lead sponsor
- Pulnovo Medical, Inc.
Record details
- Record id
cardio:ct-nct07214376- Content hash
62f99d07fc8e720a280491ecfff3c4386258b9d63aaf0512386c015bd865bad8